Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more
Paradigm Biopharmaceuticals Limited (PBIGF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.367x
Based on the latest financial reports, Paradigm Biopharmaceuticals Limited (PBIGF) has a cash flow conversion efficiency ratio of -0.367x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.77 Million) by net assets ($21.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Paradigm Biopharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Paradigm Biopharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Paradigm Biopharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Paradigm Biopharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
A Plus Asset Advisor Co Ltd
KO:244920
|
0.027x |
|
Japan Display Inc
PINK:JNNDF
|
1.051x |
|
Husteel
KO:005010
|
-0.039x |
|
HEXAOM S.A. EO -18
F:88M
|
N/A |
|
Dimand S.A.
AT:DIMAND
|
N/A |
|
Nexity SA
PINK:NNXXY
|
0.008x |
|
Sunflag Iron And Steel Company Limited
NSE:SUNFLAG
|
0.020x |
|
South Atlantic Bancshares Inc
OTCQX:SABK
|
N/A |
Annual Cash Flow Conversion Efficiency for Paradigm Biopharmaceuticals Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Paradigm Biopharmaceuticals Limited from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $21.18 Million | $-15.99 Million | -0.755x | +72.75% |
| 2024-06-30 | $23.81 Million | $-65.94 Million | -2.770x | -229.06% |
| 2023-06-30 | $53.68 Million | $-45.19 Million | -0.842x | -10.60% |
| 2022-06-30 | $42.31 Million | $-32.21 Million | -0.761x | -70.56% |
| 2021-06-30 | $78.27 Million | $-34.93 Million | -0.446x | -378.45% |
| 2020-06-30 | $108.18 Million | $-10.09 Million | -0.093x | -21.34% |
| 2019-06-30 | $82.81 Million | $-6.37 Million | -0.077x | +82.28% |
| 2018-06-30 | $13.86 Million | $-6.01 Million | -0.434x | -29.92% |
| 2017-06-30 | $13.39 Million | $-4.47 Million | -0.334x | -4.51% |
| 2016-06-30 | $11.23 Million | $-3.59 Million | -0.319x | -284.01% |
| 2015-06-30 | $14.46 Million | $-1.20 Million | -0.083x | -102.05% |
| 2014-06-30 | $-151.87K | $-617.72K | 4.068x | -- |